Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to GALNT7 (ENSG00000290017)
- Target
- ENSG00000290017
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other (non-coding RNA class)
01
Overview
The gene ENSG00000290017 encodes a long non-coding RNA (lncRNA) antisense to the GALNT7 gene locus. This RNA is classified as a natural antisense transcript (NAT)[1][3], and such RNAs are known to regulate the expression of their sense counterparts through several possible processes including transcriptional interference, RNA masking, and modulation of chromatin states[2][4][6]. Although the biological function of this specific transcript is not fully elucidated, antisense lncRNAs in general can modulate the expression of sense genes, influence mRNA processing or stability, and affect gene silencing via epigenetic modifications. There is currently no evidence that this antisense lncRNA is directly involved in disease or is a therapeutic target. Its sense gene, GALNT7 (Polypeptide N-acetylgalactosaminyltransferase 7), is a protein-coding gene implicated in cancer, but the role of the antisense transcript in pathology is not established[1][5][7].
- Other names
- Antisense to GALNT7lncRNA antisense to GALNT7
02
Biological functions
Regulation of gene expression (as antisense lncRNA)Transcriptional interference of GALNT7 sense transcriptPotential involvement in chromatin modification/epigenetic regulationmRNA stability and RNA masking
Beyond the preview
Go deeper on Novel transcript, antisense to GALNT7 (ENSG00000290017).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel transcript, antisense to GALNT7 (ENSG00000290017).